Source: GlobesNewswire Journey Medical Corporation (“Journey Medical”), a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions, and a subsidiary of Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), today announced that it has launched an initial public offering of 3,200,000 shares…...

Source: FierceBiotech When Amgen splashed $400 million upfront on Kyowa Kirin’s anti-OX40 antibody, the world was yet to see midphase data on the prospect. Amgen and Kyowa lifted the lid on the data over the weekend in a presentation of phase 2 results in eczema patients. The clinical trial randomized 274 adults…...

Source: PR Newswire Crown Laboratories, ("Crown"), a leading, fully integrated, global skincare company and a Hildred Capital Management LLC ("Hildred") portfolio company, and L Catterton, the largest global consumer-focused private equity firm, today announced that they have entered into a definitive agreement under which Crown will acquire StriVectin. The transaction is expected…...

Source: Cassiopea   Cassiopea SpA (SIX: SKIN), a specialty pharmaceutical company developing and preparing to commercialize prescription drugs with novel mechanisms of action (MOA) to address long-standing essential dermatological conditions, and Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, “Sun Pharma” and includes its subsidiaries…...

Source: GlobeNewswire Journey Medical Corporation (“Journey Medical”), a partner company of Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), today announced an agreement with Dr. Reddy’s Laboratories Ltd. (“Dr. Reddy’s”) for the collaborative development and commercialization of the DFD-29 program (Minocycline Modified Release Capsules 40 mg) for the treatment of rosacea. Journey…...

Source: Fierce Pharma The verdict is in: The FDA has approved Biogen’s controversial Alzheimer’s treatment aducanumab. The FDA’s approval on Monday is set to cause a ripple effect among drugmakers and researchers studying the elusive disease, the sixth leading cause of death in the U.S., and comes after months of intense controversy over…...

Source: GlobeNewswire The first and only prescription cloth towelette approved to treat primary axillary hyperhidrosis in people nine-years of age and older is Journey Medical’s seventh marketed dermatology product Journey Medical Corporation (“Journey Medical”), a partner company of Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), today announced that it has entered…...

Source: Globe Newswire Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), today announced that Journey Medical Corporation (“Journey Medical”), a partner company of Fortress, in-licensed and launched an oral isotretinoin under the brand name Accutane® (isotretinoin capsules USP) in the U.S. Accutane is an oral medication that is indicated for the treatment of…...

Source: FierceBiotech   The FDA has cleared a new type of device worn around the back of the neck by athletes ages 13 and up, to help protect them from brain injuries caused by typically lighter, but repeated, impacts during sports. The Q-Collar, developed by Q30 Innovations, doesn’t replace helmets…...

Source: FierceHealthcare UnitedHealth Group's Optum unit has agreed to buy Change Healthcare for $7.84 billion in cash plus about $5 billion in debt, the companies said on Wednesday. The acquisition will strengthen the insurer's portfolio of healthcare technology services and capabilities. Change Healthcare will join with OptumInsight to provide software…...